课题基金 / 基金详情

Development of the Gene-missile therapy against human malignant gliomas using monocyte as a carrier.

Development of the Gene-missile therapy against human malignant gliomas using monocyte as a carrier.
使用单核细胞作为载体开发针对人类恶性胶质瘤的基因导弹疗法。
批准号:
09671431
负责人:
TAKESHIMA Hideo
金额:
$1.98万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

TAKESHIMA Hideo的其他基金

相似基金

相关文献

中文摘要
翻译
人类单核细胞趋化蛋白-1受体被命名为hCCR2,是人类免疫缺陷病毒进入细胞所必需的辅助受体,也是单核细胞趋化蛋白-1的受体,单核细胞趋化蛋白-1是C-C趋化因子家族的成员,介导单核细胞趋化。为了阐明hCCR2转录调控的分子机制,我们克隆并测序了hCCR2基因,全长约8kb,由三个外显子和两个内含子组成。在5‘-侧翼区,存在典型的哺乳动物启动子共同元件,即CAAT盒和TATA盒,导致了单一的转录起始点。此外,我们还发现了成簇的组织特异性顺式调控元件,如GATA共识序列、Oct-1结合序列和CAAT/增强子结合蛋白结合序列。不同启动子缺失的荧光素酶分析和凝胶迁移率改变分析表明,THP-1细胞的基础活性需要三个位于-89到118区域的顺式调控元件。其中一个元件是TATA盒上游36-bp的八聚体序列;它主要与Oct-1结合,并能够增加转录活性。另外两个元件是CAAT/增强子结合蛋白家族的串联识别位点,位于5‘-非翻译区,解释了hCCR2的转录激活和组织特异性。
英文摘要
The human monocyte chemoattractant protein-1 receptor designated hCCR2 is an essential co-receptor in cell entry by the human immunodeficiency virus as well as a receptor for monocyte chemoattractant protein-1, a member of the family of C-C chemokines that mediate monocyte chemotaxis. To elucidate the molecular mechanisms underlying the transcriptional regulation of hCCR2, we cloned and sequenced the hCCR2 gene ; it was approximately 8 kb in length and consisted of three exons divided by two introns. In the 5'-flanking region, there were the typical mammalian promoter consensus elements, a CAAT box and a TATA box, resulting in a single transcription initiation site. In addition, we found clustered tissue-specific cis-regulatory elements such as GATA consensus sequences, Oct-1 binding sequences, and CAAT/enhancer-binding protein binding sequences. Luciferase assays with various promoter deletions and gel mobility shift assays indicated that three cis-regulatory elements located within the region from -89 to +118 are required for basal activity in THP-1 cells. One element is an octamer sequence 36-bp upstream from the TATA box ; it binds mainly to Oct-1 and is capable of increasing transcriptional activity. The other two elements, which are tandem recognition sites of the CAAT/enhancer-binding protein family, are located in the 5'-untranslated region and account for the transcriptional activation as well as the tissue specificity of hCCR2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Takeshima,H.et al.: "Monocyte chemoattractant protein-1(MCP-1)derived from human malignant glioma.-Biological meanings of its expression and application for the treatment of malignant glioma." Research Trends. (in press). (1999)
Takeshima,H.et al.:“源自人恶性神经胶质瘤的单核细胞趋化蛋白-1(MCP-1)。-其表达的生物学意义及其在治疗恶性神经胶质瘤中的应用。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
竹島秀雄,他: "ヒト単球遊走因子受容体の発現調節機構の解明" 神経免疫研究. 10. 142-145 (1997)
Hideo Takeshima 等:“阐明人单核细胞趋化因子受体表达的调节机制”《神经免疫学研究》10. 142-145 (1997)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamamoto,K.,Takeshima,H.,et al.: "Cloning and functional characterization of the 5'-flanking region of the human monocyte chemoattractant protein-1 receptor(CCR2)gene." J.Biol.Chem.274・8. 4646-4654 (1999)
Yamamoto, K.、Takeshima, H. 等:“人单核细胞趋化蛋白 1 受体 (CCR2) 基因 5 侧翼区域的克隆和功能表征。J.Biol.Chem.274・8” .4646-4654 (1999)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
9
    Identification of the novel molecular marker for oligodendroglial tumor using induced differentiation system against glioma stem cell.
    • 批准号:
      20390387
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.56万
    • 财政年份:
      2008
    • 负责人:
      TAKESHIMA Hideo
    • 依托单位:
    Mechanisms underlying inhibition of tumor-immunology in malignant glioma and development of immune-activation therapy using suicide-chimeric molecule
    Development of the clinical diagnosis and treatment of CNS germinoma using KIT as a target
    • 批准号:
      15591536
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2003
    • 负责人:
      TAKESHIMA Hideo
    • 依托单位:
    Development of chemokine-cocktail therapy against hyman malignant gliomas using lymphocyte-specific chemokines
    • 批准号:
      13671451
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      2001
    • 负责人:
      TAKESHIMA Hideo
    • 依托单位:
    国内基金
    海外基金
    cGAS-STING通路调控单核细胞活化参与Graves病发病的机制研究
    • 批准号:
      82370787
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      王曙
    • 依托单位:
    CCL8介导ALA光动力治疗皮肤鳞状细胞癌的效应与机制研究
    • 批准号:
      81602396
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      18.0万元
    • 批准年份:
      2016
    • 负责人:
      吉杰
    • 依托单位:
    小胶质细胞的IL-6/JAK/STAT3/MCP-1信号途径在MS/EAE发病过程中的作用
    • 批准号:
      81070958
    • 项目类别:
      面上项目
    • 资助金额:
      32.0万元
    • 批准年份:
      2010
    • 负责人:
      程琦
    • 依托单位: